Webinar | 10.03.2023
NICE recommends Echosens’ liver diagnostic solution for assessment of liver fibrosis and cirrhosis
The National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued landmark guidance recommending the use of FibroScan®, citing that it may improve the early detection of liver disease in primary and community care settings.
NICE has found that the non-invasive technology from Echosens is a safe and effective way to improve patient outcomes and create a more efficient system for diagnosing liver disease in the early stages.
This groundbreaking recommendation will allow FibroScan® patients to receive faster results in the diagnostic patient pathway and outside secondary care. As a result, this technology has the potential to revolutionize how healthcare providers diagnose and treat patients with liver conditions, such as NAFLD, NASH, fibrosis and cirrhosis, in a matter of minutes.
The NICE guidance includes evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders for adoption in the National Health System (NHS).